Form 4: Director John DeFord Receives Maravai Equity Grant

Director John DeFord was granted 46,293 restricted stock units in Maravai LifeSciences Holdings, Inc.

Summary

• Director John DeFord acquired 46,293 restricted stock units (RSUs) of Maravai LifeSciences Holdings, Inc. (MRVI) on May 26, 2026.
• The grant was issued under the company's 2020 Omnibus Incentive Plan.
• The RSUs vest in full on the earlier of one year from the grant date or the 2027 annual meeting of stockholders.
• Following this transaction, the director's total beneficial ownership of Class A Common Stock is 205,478 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The grant results in minor dilution to existing shareholders.

Risks

• Standard equity market volatility risks associated with holding company stock.

Future Outlook

The RSUs are scheduled to vest in full by May 2027 or upon the date of the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the life sciences sector to ensure long-term alignment with shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices for mid-cap biotechnology and life sciences companies.
• Vesting schedules of one year are common for annual director equity retainers in the industry.

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the 46,293 RSUs by May 2027 or the 2027 annual meeting.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Form 4, Insider Transaction, Equity Grant, Director Compensation